



**CANM  
ACMN**

**CANM 2019 Annual Scientific Meeting  
Réunion annuelle de l'ACMN 2019  
February 7-9, 2019 / 7 au 9 février 2019**

**Hôtel Le Concorde  
Québec City**



**PO Box 4383, Station 'E', Ottawa, ON K1S 2L0**

**Tel: 613-882-5097 / Email: [canm@canm-acmn.ca](mailto:canm@canm-acmn.ca) / Website: [www.canm-acmn.ca](http://www.canm-acmn.ca)**

## 2019 CANM Annual Conference

### THERANOSTICS AND INTERNATIONAL COLLABORATIVE EFFORTS

#### Overall objectives of the conference:

1. Maintain competence on a wide variety of up-to-date topics in Nuclear Medicine
2. Discuss hot new topics
3. Establish a network of Nuclear Medicine specialists
4. Promote Nuclear Medicine as a specialty

Please note that 25% of allowed time to each speaker will be reserved for questions from participants.

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program (MOC) of the Royal College of Physicians and Surgeons of Canada, and approved by the Continuing Professional Development Directorate (CPDD) of the Fédération des médecins spécialistes du Québec. You may claim up to **19 hours** for this activity (credits are automatically calculated in MAINPORT). Participation in this activity qualifies for a certificate of attendance. Participants should claim a number of hours consistent with their attendance.

Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association (AMA), physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at [www.ama-assn.org/go/internationalcme](http://www.ama-assn.org/go/internationalcme).

\*\*\*\*\*

La présente activité est une activité d'apprentissage collectif agréée (section 1), au sens que lui donne le programme de Maintien du certificat du Collège royal des médecins et chirurgiens du Canada; elle a été approuvée par la direction du Développement professionnel continu de la Fédération des médecins spécialistes du Québec.

Vous pouvez déclarer un maximum de **19 heures** (les crédits sont calculés automatiquement dans MAINPORT). Une participation à cette activité donne droit à une attestation de présence. Les participants doivent réclamer un nombre d'heures conforme à la durée de leur participation.

En vertu d'une entente conclue entre le Collège royal des médecins et chirurgiens du Canada et l'American Medical Association (AMA), les médecins peuvent convertir les crédits obtenus au titre du programme de MDC du Collège royal en *crédits de catégorie 1 de l'AMA PRAMC*. Vous trouverez l'information sur le processus de conversion des crédits du programme de MDC du Collège royal en crédits de l'AMA à l'adresse [www.ama-assn.org/go/internationalcme](http://www.ama-assn.org/go/internationalcme)

## 2019 CANM ANNUAL CONFERENCE

### THURSDAY, FEBRUARY 7, 2019

1200 - 1630	<b>CANM Board Meeting (closed)</b>	<i>Pilot</i>
0800 - 1500	<b>Exhibits Set-up</b>	<i>Foyer</i>
1600 - 1930	<b>REGISTRATION</b>	<i>Foyer</i>
1800 - 1930	<b>WELCOME RECEPTION WITH EXHIBITORS</b> <i>Appetizers and beverages will be served</i>	<i>Foyer</i>
1930 - 2130	<b>CANM Industry Forum (closed)</b>	<i>Pilot</i>

1930 - 2100	<b>CANM Residents' Forum (residents only)</b> Moderators: Denise Chan & Jonathan Abele	<i>Borduas</i>
-------------	---	----------------

1930-1950	<b>Advocacy for Nuclear Medicine - Jean-Luc Urbain/Paige Bennett</b> <i>Objectives: Discuss characteristics of adult learners. Use learner needs assessments in nuclear medicine education. Apply Socratic Dialogue during clinical read outs.</i>
1950-2010	<b>Royal College Changes to the Specialty - Antoine Leblond</b>
2010-2030	<b>Fellowships and Future Needs for the Next 5-10 Years for Nuclear Medicine - Jean-Mathieu Beaugard &amp; David Laidley</b>
2030-2100	<b>Discussion</b>
2100-ON	<b>Informal Gathering (location TBD)</b>

### FRIDAY, FEBRUARY 8, 2019

0700 - 1700	<b>REGISTRATION-INSCRIPTION</b>	<i>Foyer</i>
-------------	---------------------------------	--------------

0700 - 0745	<b>SUNRISE SYMPOSIUM with Breakfast - Sn-117m Homogeneous Colloid: A New Therapeutic Agent in Canada</b> Chair: Daniel Picard <b>Objectives:</b> <ul style="list-style-type: none"> <li>• Describe the manufacturing of tin-117m and tin-117m colloid.</li> <li>• Review the associated radiation exposure based of injected doses.</li> </ul> <b>Speakers:</b> Cynthia Doerr and Nigel Stevenson	<i>Krieghoff-Suzor-Côté</i>
-------------	---	-----------------------------

0700 - 1700	<b>EXHIBITS CONTINUE</b>	<i>Foyer</i>
-------------	--------------------------	--------------

0700 - 1700	<b>POSTERS SET-UP</b>	<i>Krieghoff-Suzor-Côté</i>
-------------	-----------------------	-----------------------------

0800 - 0815	<b>WELCOME-MOT DE BIENVENUE</b> Jean-Luc Urbain & Jean-Mathieu Beaugard	<i>Krieghoff-Suzor-Côté</i>
-------------	--	-----------------------------

<p><b>0815 - 1000</b></p>	<p><b>SESSION 1A – THERANOSTICS: NET-OVERVIEW AND NUCLEAR DIAGNOSIS</b>                  Chairs: Jean-Mathieu Beaugregard/Sarah-Jeanne Côté-Martin  <b>Objectives:</b></p> <ul style="list-style-type: none"> <li>• To review the anatomic and pathologic diversity of neuroendocrine tumors.</li> <li>• To explain the scope of systemic therapies available for neuroendocrine tumors.</li> <li>• To identify current challenges in the optimization of outcomes for patients with neuroendocrine tumors.</li> </ul>	<p>Krieghoff-Suzor-Côté</p>
	<p><b>0815-0900 NET 101, Current Tx and Challenges</b> Daniel Rayson</p> <p><b>0900-0930 Ga-68 Octreotate</b> Éric Turcotte</p>	
<p><b>0930-1000</b></p>	<p><b>REFRESHMENT BREAK-PAUSE</b></p>	<p>Foyer</p>
<p><b>1000 - 1200</b></p>	<p><b>SESSION 1B – THERANOSTICS: NET PRRT TRIAL RESULTS &amp; TEST YOUR NET</b>                  Chairs: Norman Laurin/ Guillaume Chaussé  <b>Objectives:</b>                  To detail and illustrate the NET radionuclide therapy available in Canada.</p>	<p>Krieghoff-Suzor-Côté</p>
	<p><b>1000-1030 PRRT in London, ON</b> David Laidley</p> <p><b>1030-1100 PRRT in Québec</b> Jean-Mathieu Beaugregard</p> <p><b>1100-1130 PRRT in Ontario</b> Rebecca Wong</p> <p><b>1130-1200 PRRT in Edmonton</b> Sandy McEwan</p>	
<p><b>0815 - 1200</b></p>	<p><b>SESSION 2 – SESSION DES TECHNOLOGUES</b>                  Modérateurs: Félix Dery-Jeanson et Nancy Lafrenière</p>	<p>Borduas</p>
	<p><b>0815-0915 Atelier formatif sur la sélection d'une hotte</b> Chantal Asselin et Nancy Lafrenière</p> <p><b>0915-0930 Présentation de cas clinique</b> Félix Dery-Jeanson</p> <p><b>0930-1000 Pause</b></p> <p><b>1000-1100 Collaboration entre la pharmacie et la médecine nucléaire pour la formation des technologues en champs stérile sous la hotte</b> Xavier Deschamps et Gilles-Philippe Harvey  <i>Objectives : Connaître les principales politiques et procédures qui doivent être mises en œuvre pour encadrer le travail sous hotte stériles. Comprendre les différentes étapes menant à l'obtention d'une certification en manipulations stériles. (X. Deschamps)</i></p>	

	<p><b>1100-1200 La thérapie personnalisée au Lu177</b>          Frédéric Arsenault  <i>Objectives : Comprendre et classifier les tumeurs neuroendocrines. Identifier les patients éligibles à la PRRT. Différencier la PRRT personnalisée de la PRRT empirique.</i></p>	
<p><b>1200 - 1300</b></p>	<p><b>LUNCHEON SYMPOSIUM: Theranostics and the Future of Nuclear Medicine</b>          Chair: Denise Chan/Jean-Luc Urbain  <b>Objectives:</b></p> <ul style="list-style-type: none"> <li>• To define the concept of Theranostics.</li> <li>• To explain and illustrate the potentials of Theranostics for Nuclear Medicine</li> </ul> <p><b>Speaker:</b> Satoshi Minoshima, MD, PhD (President SNMMI)</p>	<p>Krieghoff-Suzor-Côté</p>
<p><b>1300 - 1445</b></p>	<p><b>SESSION 3 – QUANTITATION IN NUCLEAR MEDICINE AND THE FUTURE OF DIGITAL PET</b>          Chair: Anita Thomas  <b>Objectives:</b></p> <ul style="list-style-type: none"> <li>• To define and demonstrate the usefulness of quantitation in nuclear medicine.</li> <li>• To identify and evaluate the various parameters affecting the SUVs.</li> </ul>	<p>Krieghoff-Suzor-Côté</p>
	<p><b>1300-1330 SPECT SUV</b>          TBD</p> <p><b>1330-1445 PET SUV &amp; The Future of Digital PET</b>          Osama Mawlawi</p>	
<p><b>1445 -1500</b></p>	<p><b>REFRESHMENT BREAK-PAUSE</b></p>	<p>Foyer</p>
<p><b>1300- 1600</b></p>	<p><b>SESSION 4 – SESSION DES TECHNOLOGUES</b>          Modérateurs: Félix Dery-Jeanson et Nancy Lafrenière</p>	<p>Borduas</p>
	<p><b>1300-1345 Radioprotection et les thérapies en médecine nucléaire</b>          Kim Pomerleau-Jobidon</p> <p><b>1345-1445 Expérience en Australie: PSMA-Ga68 et PSMA-Lu177</b>          Alexis Beaulieu</p> <p><b>1445-1500 Pause</b></p> <p><b>1500-1600 Blindage d'un nouveau service de médecine nucléaire: Conception, radioprotection et coûts</b>          Robert Ouellet  <b>Objectives:</b> Review technical and clinical radiation shielding criteria. Appreciate the impact of TEP/CT rapid technological evolution on the shielding requirements. Review the shielding conception of a future Lu177 theratogenic treatment room</p>	
<p><b>1500 -1545</b></p>	<p><b>ABSTRACT PRESENTATIONS</b>          Chairs: Salem Yuoness  <b>Objectives:</b></p> <ul style="list-style-type: none"> <li>• To enable the young NM physicians in Canada to present their research.</li> <li>• To describe, review and demonstrate interesting and unique nuclear medicine cases.</li> </ul>	<p>Krieghoff-Suzor-Côté</p>

**ERIC LEPP COMPETITION WINNER PRESENTATION**

**1500-1507** WBC Scintigraphy for Identifying Infected Liver Cysts - *Chris McIntosh (#EL-002)*

**SELECTED ABSTRACTS ORAL PRESENTATIONS**

**1508-1516** Misadministration of Sn-117m Colloid During Radiosynoviorthesis Presents No Safety Concerns – *Cynthia Doerr (#003)*

**1516-1524** Botulinum Toxin Intraglandular Injection to Block PSMA Salivary Gland Uptake - *Guillaume Chaussé (#006)*

**1524-1532** Utility of 111In-Pentetreotide Scintigraphy for The Evaluation of Appendiceal Neuroendocrine Tumors - *Chris McIntosh (#012)*

**1532-1540** Disappearance of Myocardial Perfusion Defects on Prone SPECT Imaging - *Zamzam KS Al Bimana (#015)*

**1545-1700 INTERNATIONAL OUTREACH**

Chairs: François Lamoureux/ Kathy Flood

*Krieghoff-Suzor-Côté*

**Objectives:**

- *To describe and evaluate the role and benefits of the different regional NM organizations in the world.*
- *To enable Canadian NM professionals to network with peers from across the globe.*

**1545-1600 AOFNMB**

Jun Hatazawa

**1600-1630 SNMMI**

Paige Bennett: Women in Nuclear Medicine

**1630-1700 ASNC**

Kathy Flood: ASNC: Your Nuclear Cardiology Companion

**1700-1800 AWARDS & POSTERS PRESENTATION with reception**

*Beverages will be served*

*Krieghoff-Suzor-Côté*

**1800-1830 CANM AGM**

*Krieghoff-Suzor-Côté*

**SATURDAY, FEBRUARY 9, 2019**

**0700 - 1000 REGISTRATION-INSCRIPTION**

*Foyer*

**0700 - 0800 SUNRISE SYMPOSIUM with Breakfast: Radionuclide therapy and Skin**

**Cancer: Focus on Re-188**

Chair: Philip Cohen

**Objectives:**

- *To recognize and evaluate the advantages and disadvantage of current and upcoming treatment options*
- *To identify the various types of treatment for non-melanoma skin cancers.*

**Speaker:** Shannon Brown and Tassia Godoy

*Krieghoff-Suzor-Côté*

**0700 - 1630 EXHIBITS CONTINUE**

*Foyer*

**0700 - 1630 POSTERS**

*Krieghoff-Suzor-Côté*

<p><b>0800 - 1015</b></p>	<p><b>SESSION 5 – THERANOSTICS: PROSTATE CANCER</b>            Chair: Kalevi Kairemo  <b>Objectives:</b></p> <ul style="list-style-type: none"> <li>• To discuss practical treatment options in metastatic prostate cancer.</li> <li>• To explain the PSMA PET/CT indications and test performance for the treatment of prostate cancer.</li> <li>• To illustrate and demonstrate the Finnish PET and RadioLigand Therapy experience in prostate cancer.</li> <li>• To describe and review the Canadian RLT clinical trial.</li> </ul>	<p>Krieghoff-Suzor-Côté</p>
	<p><b>0800-0845 Prostate Cancer 101: mCRPC, Treatment &amp; Challenges</b> Frédéric Pouliot</p> <p><b>0845-0915 Canadian PSMA PET Experience</b> Stephan Probst</p> <p><b>0915-0945 Finnish PSMA PET and RLT Experience</b> Kalevi Kairemo</p> <p><b>0945-1015 Canadian PSMA RLT Trial</b> François Bénard</p>	
<p><b>0800- 1015</b></p>	<p><b>SESSION 6 – SESSION DES TECHNOLOGUES</b>            Modérateurs: Félix Dery-Jeanson et Nancy Lafrenière</p>	<p>Borduas</p>
	<p><b>0800-1000 Atelier sur le CT en médecine nucléaire et au TEP</b> Jonathan Boivin  <b>Objectives:</b> Identifier les composants principaux d'un CT en médecine nucléaire et décrire son fonctionnement. Interpréter les différents paramètres d'acquisition d'un CT et reconnaître les principaux artéfacts. Acquérir les concepts de dose, de radioprotection et de contrôle qualité au CT et le comparer avec les radionucléides.</p> <p><b>1000-1015 Présentation de cas clinique</b> Félix Dery-Jeanson</p>	
<p><b>1015 - 1045</b></p>	<p><b>REFRESHMENT BREAK-PAUSE</b></p>	<p>Foyer</p>
<p><b>1045- 1215</b></p>	<p><b>Round-table on the Future of NM Practice in Canada, with Respect to Radionuclide Therapy</b>            Chairs: Jean-Mathieu Beauregard/Denise Chan  <b>Objectives:</b></p> <ul style="list-style-type: none"> <li>• To discuss in an open forum the future of Nuclear Medicine practice and training in Canada, with respect to radionuclide therapy.</li> <li>• To review, explain and understand the training needs for PRRT, outline current deficiencies in training and elaborate ideas on how to fill these deficiencies.</li> <li>• To discuss the challenges of starting a Radionuclide Therapy Program.</li> <li>• To discuss and possibly reach a consensus on the training and professional requirements to administer Radionuclide Therapy in Canada.</li> </ul> <p><b>Panel:</b> Jonathan Abele, Andrew Ross, François-Alexandre Buteau, Olfat Kamel-Hasan (TBC), David Laidley, Sandy McEwan and Salem Yuoness</p>	<p>Krieghoff-Suzor-Côté</p>

<p><b>1045-1215</b></p>	<p><b>SESSION 7 – SESSION DES TECHNOLOGUES</b>          Modérateurs: Félix Dery-Jeanson et Nancy Lafrenière</p>	<p><i>Borduas</i></p>
	<p><b>1045-1145</b>    <b>Présentation sur le cyclotron et les isotopes exotiques produits</b>          Brigitte Guérin</p>	
	<p><b>1145-1215</b>    <b>Présentation de cas clinique</b>          Félix Dery-Jeanson</p>	
<p><b>1215-1315</b></p>	<p><b>LUNCHEON SYMPOSIUM: Brain PET</b>          Chair: Paige Bennett  <b>Objectives:</b></p> <ul style="list-style-type: none"> <li>• <i>To learn the recognized indications for FDG, amyloid, avoid unrecognized use.</i></li> <li>• <i>To understand what part of Alzheimer we are looking at with amyloid tracers.</i></li> <li>• <i>To develop a reasonable perspective on the place of imaging in the diagnostic algorithm of neurodegenerative diseases in 5 years.</i></li> </ul> <p><b>Speaker:</b> Jean-Paul Soucy</p>	<p><i>Krieghoff-Suzor-Côté</i></p>
<p><b>1315 -1500</b></p>	<p><b>SESSION 8 – ARE YOU READY FOR THE TRENDS IN NUCLEAR MEDICINE IN 2019-2020?</b>          Chair: Andrew Ross  <b>Objectives:</b></p> <ul style="list-style-type: none"> <li>• <i>To describe and learn the basics of kinetic modeling.</i></li> <li>• <i>To review the potential benefits provided by dynamic PET imaging in clinical practice.</i></li> <li>• <i>To understand the most recent technological advances enabling dynamic whole-body PET imaging.</i></li> <li>• <i>To comprehend the use Tc-99m pyrophosphate imaging in order to identify the transthyretin variant of cardiac amyloidosis.</i></li> <li>• <i>To demonstrate the clinical utility and potential limitations of FDG PET imaging for identifying active cardiac sarcoidosis.</i></li> <li>• <i>To explain the difference between social media and traditional media.</i></li> <li>• <i>To analyze the myriad uses of social media in healthcare.</i></li> <li>• <i>To review how to employ professional/ethical guidelines when using social media in healthcare.</i></li> </ul>	<p><i>Krieghoff-Suzor-Côté</i></p>
	<p><b>1315-1345</b>    <b>Does Dynamic PET Imaging Have a Future in Clinical Oncologic Practice?</b>          Arman Rahmim</p>	
	<p><b>1345-1415</b>    <b>Nuclear Diagnosis of Infiltrative Cardiac Disease</b>          Richard Brunken</p>	
	<p><b>1415-1445</b>    <b>Nuclear Medicine and Social Media: A New Paradigm</b>          Paige Bennett</p>	
<p><b>1315-1445</b></p>	<p><b>SESSION 9 - SESSION DES TECHNOLOGUES</b>          Modérateurs: Félix Dery-Jeanson et Nancy Lafrenière</p>	<p><i>Borduas</i></p>



**1315-1415 Présentation sur le Datscan**

Mary Dalipaj

**Objectives:** *Introduction to DaTscan and Parkinson Syndromes. Module 1: Properties of DaTscan. Module 2: Patient preparation, dose administration, acquisition and positioning. Module 3: Image processing, orientation and display. Module 4: Review and interpretation, image examples.*

**1415-1445 Dosimétrie pour les patients traités en médecine nucléaire**

Nancy Lafrenière

**Objectives:** *Comprendre la démarche scientifique derrière la thérapie personnalisée en PRRT. Connaître la bio distribution et les organes cibles.*

**1445-1515 REFRESHMENT BREAK-PAUSE**

Foyer

**1515-1630 SESSION 10– ALL YOU NEED TO KNOW ABOUT DATSCAN**

Chairs: François Lamoureux/Jean-Luc Urbain

**Objectives:**

- *To describe and review the role of nuclear imaging in movement disorders*
- *To illustrate the role and limitations of DaTScan in the diagnosis and management of movement disorders*
- *To test the understanding and knowledge of the attendees on the role of DaTScan in the diagnosis and management of movement disorders*

**Speaker:** Christian Scheiber

Krieghoff-Suzor-Côté

**1630**

**CLOSURE-FERMETURE**

**SCIENTIFIC COMMITTEE – 2018-2019**

Jean-Luc Urbain, co-chair  
Jean-Mathieu Beauregard, co-chair  
<https://canm-acmn.ca/meetingdocuments>

Jonathan Abele  
Denise Chan  
Khun Visith Keu  
Nancy Lafrenière  
Salem Yuoness

***This activity has been made possible thanks to the educational support of the following sponsors:  
La tenue de cette activité a été rendue possible grâce à une subvention à visée éducative de:***

**GOLD:**

Cyclomedica  
Jubilant Draximage  
Isologic  
Lantheus Medical Imaging

**SILVER:**

GE Healthcare

**BRONZE +:**

Advanced Accelerator  
Applications Canada (AAA)  
Curium  
Siemens Healthineers

**BRONZE:**

Hermes

**OTHER:**

Bayer Healthcare  
Oncobeta  
Serene  
Tourism Québec

February 4, 2019

**A special thanks to the following exhibitors:  
*Nous tenons à remercier les exposants suivants :***

Advanced Accelerator Applications Canada Inc.

Bayer Healthcare

Canadian Nuclear Laboratories

Comcer Group

Curium

Cyclomedica Canada Limited

GE Healthcare Canada Inc.

Hermes Medical Solutions Canada Inc.

Isologic Radiopharmaceutiques

Jubilant DraxImage Inc.

Lantheus Medical Imaging

MIM Software Inc.

Philips Healthcare

Segami Corporation

Servier Canada

Siemens Canada

Trasis

**VISIT OUR WEBSITE**

For information, please visit our Website at: <https://www.canm-acmn.ca>

The Canadian Association of Nuclear Medicine  
gratefully acknowledges  
educational support from the following sponsors:

*L'Association canadienne de médecine nucléaire  
remercie sincèrement les commanditaires suivants  
pour leur soutien didactique:*

## GOLD



## SILVER



## BRONZE +



## BRONZE



## OTHERS



Serene

